文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓纤维化患者异基因移植后的生存分析

Survival following allogeneic transplant in patients with myelofibrosis.
PubMed 文献 · Blood Adv · 2020-01-01

这项大型多中心回顾性研究分析了551例接受异基因造血细胞移植(HCT)和1377例未接受HCT的骨髓纤维化(MF)患者的总体生存(OS)。按DIPSS分层,治疗分组后第一年HCT因早期移植相关死亡(TRM)风险OS劣于非HCT;一年后Int-1及以上风险组HCT显示OS优势,且DIPSS风险越高、随访越长,HCT的OS获益幅度越大。

要点

  • 治疗分组后第一年,非HCT组OS优于HCT组:DIPSS-Int-1组HR=0.26,DIPSS-Int-2及以上组HR=0.39。
  • DIPSS低危组第一年非HCT组OS优于HCT组(HR=0.16,P=.006),一年后两组OS无显著差异(HR=1.38,P=.451)。
  • 治疗分组一年后,Int-1及以上风险组HCT组OS优于非HCT组:DIPSS-Int-1组HR=2.64,DIPSS-Int-2及以上组HR=2.55。

核心结论

  • Int-1及以上风险的MF患者接受HCT可获得长期OS优势,但代价是早期TRM风险。
  • HCT的OS获益幅度随DIPSS风险评分升高而增大,并随随访时间延长而显现。

研究设计与样本

  • 大型多中心回顾性研究,比较接受异基因HCT的551例MF患者与未接受HCT的1377例MF患者。
  • 采用Cox比例风险模型分析总体生存,并按DIPSS进行分层。

主要发现

  • 治疗分组后第一年,非HCT组OS优于HCT组:DIPSS-Int-1组HR=0.26(P<.0001),DIPSS-Int-2及以上组HR=0.39(P<.0001)。
  • DIPSS低危组治疗分组后第一年非HCT组OS优于HCT组(HR=0.16,P=.006),一年后两组OS无显著差异(HR=1.38,P=.451)。
  • 治疗分组一年后,Int-1及以上风险组HCT组OS优于非HCT组:DIPSS-Int-1组HR=2.64(P<.0001),DIPSS-Int-2及以上组HR=2.55(P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020. PMID: 32384540. doi:10.1182/bloodadvances.2019001084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。